BFM
SNTI icon

Boothbay Fund Management’s Senti Biosciences Holdings SNTI Stock Holding History

Boothbay Fund Management’s Portfolio SNTI Stock Details SNTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,950
Closed -$291K – 2633
2022
Q1 		$291K Buy
+2,950
New +$291K 0.01% 1634

Other funds holding SNTI

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return
IC
Intel Corp Santa Clara, California $470M AUM 21.74% 1-Year Est. Return
FMN
Financial Management Network Mission Viejo, California $653M AUM 17.76% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
KC
Kingfisher Capital Charlotte, North Carolina $437M AUM 41.72% 1-Year Est. Return

Boothbay Fund Management's SNTI Position: Q2 2022 in Review

Boothbay Fund Management sold out of Senti Biosciences Holdings (SNTI) in Q2 2022, closing a stake of 2,950 shares — an estimated $291K sold.

Boothbay Fund Management first reported a position in SNTI in Q1 2022 and held it in 1 quarter. The position peaked at $291K in Q1 2022. 22 funds tracked by Wall St. Rank hold SNTI as of Q2 2022.

  • Boothbay Fund Management reported no remaining Senti Biosciences Holdings position as of Q2 2022 after selling out during the quarter.
  • Boothbay Fund Management sold 2,950 Senti Biosciences Holdings shares in Q2 2022, an estimated $291K.
  • Boothbay Fund Management first reported a position in Senti Biosciences Holdings in Q1 2022 and held it in 1 quarter.
  • Boothbay Fund Management's Senti Biosciences Holdings position peaked at $291K in Q1 2022.
  • 22 funds tracked by Wall St. Rank held Senti Biosciences Holdings as of Q2 2022.

Based on Boothbay Fund Management's 13F filing for Q2 2022, filed 15 Aug 2022.